Shares of Redx Pharma Plc (LON:REDX – Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 15.52 ($0.19) and traded as low as GBX 8.02 ($0.10). Redx Pharma shares last traded at GBX 10 ($0.12), with a volume of 469,387 shares traded.
Redx Pharma Price Performance
The company has a quick ratio of 1.93, a current ratio of 1.11 and a debt-to-equity ratio of 527.00. The stock has a market capitalization of £38.90 million, a PE ratio of -100.00 and a beta of -0.53. The company has a 50-day moving average of GBX 15.52 and a 200 day moving average of GBX 20.53.
Insider Buying and Selling
In other news, insider Lisa Anson purchased 115,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The stock was purchased at an average cost of GBX 9 ($0.11) per share, for a total transaction of £10,350 ($12,784.09). 18.23% of the stock is owned by company insiders.
About Redx Pharma
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
See Also
- Five stocks we like better than Redx Pharma
- What Are Dividend Contenders? Investing in Dividend Contenders
- Hasbro’s Management Made All the Right Calls This Quarter
- Airline Stocks – Top Airline Stocks to Buy Now
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Why is the Ex-Dividend Date Significant to Investors?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.